Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2006 Jul 24:6:30.
doi: 10.1186/1471-244X-6-30.

Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons

Laurent Eckert  1 , Christophe Lançon
Affiliations
Meta-Analysis

Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons

Laurent Eckert et al. BMC Psychiatry. .

Abstract

Background: Data comparing duloxetine with existing antidepressant treatments is limited. A comparison of duloxetine with fluoxetine has been performed but no comparison with venlafaxine, the other antidepressant in the same therapeutic class with a significant market share, has been undertaken. In the absence of relevant data to assess the place that duloxetine should occupy in the therapeutic arsenal, indirect comparisons are the most rigorous way to go. We conducted a systematic review of the efficacy of duloxetine, fluoxetine and venlafaxine versus placebo in the treatment of Major Depressive Disorder (MDD), and performed indirect comparisons through meta-regressions.

Methods: The bibliography of the Agency for Health Care Policy and Research and the CENTRAL, Medline, and Embase databases were interrogated using advanced search strategies based on a combination of text and index terms. The search focused on randomized placebo-controlled clinical trials involving adult patients treated for acute phase Major Depressive Disorder. All outcomes were derived to take account for varying placebo responses throughout studies. Primary outcome was treatment efficacy as measured by Hedge's g effect size. Secondary outcomes were response and dropout rates as measured by log odds ratios. Meta-regressions were run to indirectly compare the drugs. Sensitivity analysis, assessing the influence of individual studies over the results, and the influence of patients' characteristics were run.

Results: 22 studies involving fluoxetine, 9 involving duloxetine and 8 involving venlafaxine were selected. Using indirect comparison methodology, estimated effect sizes for efficacy compared with duloxetine were 0.11 [-0.14;0.36] for fluoxetine and 0.22 [0.06;0.38] for venlafaxine. Response log odds ratios were -0.21 [-0.44;0.03], 0.70 [0.26;1.14]. Dropout log odds ratios were -0.02 [-0.33;0.29], 0.21 [-0.13;0.55]. Sensitivity analyses showed that results were consistent.

Conclusion: Fluoxetine was not statistically different in either tolerability or efficacy when compared with duloxetine. Venlafaxine was significantly superior to duloxetine in all analyses except dropout rate. In the absence of relevant data from head-to-head comparison trials, results suggest that venlafaxine is superior compared with duloxetine and that duloxetine does not differentiate from fluoxetine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagram Flow for duloxetine.
Figure 2
Figure 2
Diagram Flow for fluoxetine.
Figure 3
Figure 3
Diagram Flow for venlafaxine.
Figure 4
Figure 4
Funnel Plots. a duloxetine b fluoxetine c venlafaxine
Figure 5
Figure 5
Results: duloxetine compared with fluoxetine and venlafaxine. a efficacy (effect size scale) b response (log odds ratio) c dropouts (log odds ratio)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993;8:23–33. - PubMed
    1. Pitsikas N. Duloxetine. Curr Opin Investig Drugs. 2000;1:116–121. - PubMed
    1. Falissard B, Lothgren M, Perahia D, Garcia-Cebrian A. Meta-analyses of duloxetine in the treatment of MDD [Poster] presented at the 4th International Forum on Mood and Anxiety Disorders : abstract PO13, 19 Nov 2003. 2003.
    1. Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther. 2004;26:1446–1455. doi: 10.1016/j.clinthera.2004.09.010. - DOI - PubMed
    1. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res. 2005;39:43–53. doi: 10.1016/j.jpsychires.2004.04.011. - DOI - PubMed

MeSH terms